Marshall Anderson, MD
Internal Medicine · Burlington, NCNPI 1194766378
Payments from drug & device makers
What this record shows
This record is dominated by education: $32 of the $32 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, Novo Nordisk. That places this record below the midpoint for internal medicine clinicians in NC, where the typical reported total is $163.
Across 1 payment — averaging $32.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$32
Across 965 payments — averaging $458.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$286K
- Esperion Therapeutics, Inc.$156K
What the payments were for
- Education$32100%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 1 | $32 |
How this compares
$32 in reported general payments places this provider in the 25th percentile of 3,302 internal medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 464 | $505,497 |
| EliquisApixaban | 491 | $280,280 |
| RybelsusSemaglutide | 108 | $191,489 |
| OzempicSemaglutide | 158 | $176,279 |
| TrulicityDulaglutide | 121 | $138,558 |
| MounjaroTirzepatide | 99 | $118,988 |
| XareltoRivaroxaban | 100 | $58,164 |
| MyrbetriqMirabegron | 57 | $27,438 |
| JanuviaSitagliptin Phosphate | 35 | $26,507 |
| FarxigaDapagliflozin Propanediol | 22 | $25,464 |
| WegovySemaglutide | 12 | $21,432 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $20,464 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 48 | $15,884 |
| LinzessLinaclotide | 23 | $14,441 |
| LatudaLurasidone Hcl | 11 | $13,483 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic, Wegovy | $32 | $389,200278 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 3,302 internal medicine providers in North Carolina.
Other internal medicine in Burlington
- Nirmish ShahDurham$862K
- Eugene WrightFayetteville$839K
- Saad UsmaniCharlotte$551K
- Bhakti PaulRaleigh$536K
- Mary KlotmanDurham$478K
- Manesh PatelDurham$435K
- Millie LongChapel Hill$374K
- Marc JohnsonCharlotte$342K
- Christina CraterRaleigh$330K
- Jamy ArdWinston Salem$293K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.